The benefit/risk profile of TNF-blocking agents : Findings of a consensus panel
- Author
- HOCHBERG, Marc C1 ; LEBWOHL, Mark G2 ; PLEVY, Scott E3 ; HOBBS, Kathryn F4 ; YOCUM, David E5 6
[1] Medicine and Head, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, United States
[2] Dermatology, Department of Dermatology, Mount Sinai School of Medicine, New York, NY, United States
[3] Medicine and Immunology, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
[4] Medicine University of Colorado Health Science Center, Denver, CO, United States
[5] Medicine, University of Arizona Health Science Center, Tucson, AZ, United States
[6] Arizona Arthritis Center, Tucson, AZ, United States - Source
Seminars in arthritis and rheumatism. 2005, Vol 34, Num 6, pp 819-836, 18 p ; ref : 116 ref
- CODEN
- SAHRBF
- ISSN
- 0049-0172
- Scientific domain
- Rheumatology
- Publisher
- Elsevier, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- Adalimumab CD RA TNF-blockers benefit/risk etanercept infliximab psoriasis
- Keyword (fr)
- Adalimumab Chronique Etanercept Facteur nécrose tumorale Facteur risque Immunodépresseur Immunomodulateur Infliximab Polyarthrite rhumatoïde Psoriasis Antagoniste Anticorps monoclonal Anticytokine Facteur nécrose tumorale α Maladie autoimmune Peau pathologie Protéine fusion Protéine recombinante Rhumatisme inflammatoire Système ostéoarticulaire pathologie
- Keyword (en)
- Adalimumab Chronic Etanercept Tumor necrosis factor Risk factor Immunosuppressive agent Immunomodulator Infliximab Rheumatoid arthritis Psoriasis Antagonist Monoclonal antibody Anticytokine Tumor necrosis factor α Autoimmune disease Skin disease Fusion protein Recombinant protein Inflammatory joint disease Diseases of the osteoarticular system
- Keyword (es)
- Adalimumab Crónico Etanercept Factor necrosis tumoral Factor riesgo Inmunodepresor Inmunomodulador Infliximab Poliartritis reumatoidea Psoriasis Antagonista Anticuerpo monoclonal Anticitoquina Factor necrosis tumoral α Enfermedad autoinmune Piel patología Proteína fusionada Proteína recombinante Reumatismo inflamatorio Sistema osteoarticular patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B08 Dermatology / 002B08D Psoriasis. Parapsoriasis. Lichen
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B15 Diseases of the osteoarticular system / 002B15D Inflammatory joint diseases
- Discipline
- Dermatology Osteoarticular pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16986721
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.semarthrit.2004.11.006 
https://dx.doi.org/10.1016/j.semarthrit.2004.11.006
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1016\/j.semarthrit.2004.11.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Seminars in arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:22:\"Semin. arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"819\";s:8:\"\u0000*\u0000epage\";s:3:\"836\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0049-0172\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HOCHBERG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Marc C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:15:\"LEBWOHL, Mark G\";i:1;s:14:\"PLEVY, Scott E\";i:2;s:16:\"HOBBS, Kathryn F\";i:3;s:14:\"YOCUM, David E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SAHRBF\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1016\/j.semarthrit.2004.11.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Seminars in arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:22:\"Semin. arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"819\";s:8:\"\u0000*\u0000epage\";s:3:\"836\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0049-0172\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HOCHBERG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Marc C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:15:\"LEBWOHL, Mark G\";i:1;s:14:\"PLEVY, Scott E\";i:2;s:16:\"HOBBS, Kathryn F\";i:3;s:14:\"YOCUM, David E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SAHRBF\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1016\/j.semarthrit.2004.11.006\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1016\/j.semarthrit.2004.11.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Seminars in arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:22:\"Semin. arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"819\";s:8:\"\u0000*\u0000epage\";s:3:\"836\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0049-0172\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HOCHBERG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Marc C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:15:\"LEBWOHL, Mark G\";i:1;s:14:\"PLEVY, Scott E\";i:2;s:16:\"HOBBS, Kathryn F\";i:3;s:14:\"YOCUM, David E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SAHRBF\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1016\/j.semarthrit.2004.11.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Seminars in arthritis and rheumatism\";s:9:\"\u0000*\u0000stitle\";s:22:\"Semin. arthritis rheum\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"34\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"819\";s:8:\"\u0000*\u0000epage\";s:3:\"836\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0049-0172\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HOCHBERG\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Marc C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:15:\"LEBWOHL, Mark G\";i:1;s:14:\"PLEVY, Scott E\";i:2;s:16:\"HOBBS, Kathryn F\";i:3;s:14:\"YOCUM, David E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"SAHRBF\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:79:\"The benefit\/risk profile of TNF-blocking agents : Findings of a consensus panel\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"18\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
